baltaleucel-T

BIOLOGICAL2 trials

Sponsors

Cell Medica Ltd

Conditions

EBVHodgkin LymphomaLymphoma, Extranodal NK-T-CellLymphoma, Large B-Cell, DiffusePost-transplant Lymphoproliferative Disorder

Phase 2

Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma

TerminatedNCT01948180

Cell Medica LtdEBV, Lymphoma, Extranodal NK-T-Cell

Start: 2014-09-30End: 2018-09-07Updated: 2019-03-13

Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas

TerminatedNCT02763254

Cell Medica LtdHodgkin Lymphoma, Lymphoma, Large B-Cell, Diffuse, Post-transplant Lymphoproliferative Disorder

Start: 2016-11-30End: 2018-02-17Updated: 2019-03-26

Related Papers

Rapidly-Generated EBV-Specific T Cells (EBVST-cells) to Treat Type 2 Latency Lymphoma

Blood2016-12-021 citations